The Foundation supports research across basic, translational and clinical science to speed breakthroughs that can lead to the creation of new treatments and a better quality of life for people with Parkinson's disease.
Search or browse funded studies
Previously funded studies appear chronologically, with the most recent appearing first.
-
Therapeutic Pipeline Program, 2021Development of Compounds that Destroy Alpha-Synuclein Aggregates for the Treatment of Parkinson’s Disease
Study Rationale:
Multiple lines of evidence indicate that alpha-synuclein forms aggregates similar to those adopted by infectious prion proteins, and that these toxic clusters are responsible for the... -
Priority Biology, 2021LRRK2 Regulation of Melanoma Progression
Study Rationale:
People with Parkinson's disease (PD) are more likely to develop melanoma, and people with melanoma are more likely to develop PD than the general population. Additionally, melanoma... -
Therapeutic Pipeline Program, 2021RNA Targeting Small Molecules as Therapeutics for Parkinson's
Study Rationale:
Abnormal clumping of the protein alpha-synuclein is a hallmark of Parkinson's disease (PD) and a likely cause of neurodegeneration and, ultimately, symptoms. One of the causes... -
Research Grant, 2021Codevelopment of Small-molecule Regulators of Miro1 for the Treatment of Parkinson’s Disease and a GLP Clinical Biomarker Assay
Study Rationale:
The mitochondrial protein Miro1 is elevated in more than 90% of all Parkinson’s disease (PD) patients of both genetic and sporadic forms. The high level of Miro1 is a pathogenic... -
Research Grant, 2021Genotyping of Lymphoblastoid Cell Lines from Familial and Sporadic Parkinson’s Disease
Study Rationale:
Our previous studies show deficits in a cell activity called centrosome cohesion in cells from people with Parkinson’s disease (PD) and a LRRK2 mutation. These deficits are reverted... -
Priority Biology, 2021Developing New Therapeutic Drugs for Parkinson’s in Human Stem Cell Neurons
Study Rationale:
Neurons derived from stem cells from people with Parkinson’s disease offer an opportunity to perform drug and target discovery. We completed a screen of 4,000 drug compounds in such...

Apply for a Grant
Our funding programs support basic, translational and clinical research from academia and industry.